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Abstract
Evaluation of bone marrow involvement (BMI) is paramount in diffuse large B-cell lymphoma
(DLBCL) for prognostic and therapeutic reasons. PET/CT scanner (PET) is now a routine
examination for the staging of DLBCL with prognostic and therapeutic implications. This
study evaluates the role of PET for detecting marrow involvement compared to bone marrow
biopsy (BMB). This monocentric study included 54 patients diagnosed with DLBCL between
2009 and 2013 and who had FDG PET/CT in a pre-treatment setting. A correlation analysis
of the detection of BMI by PET and BMB was performed. A prognostic evaluation of BMI by
BMB and/or PET/CT and correlation with an overall 2-year survival were analyzed. PET
was more sensitive for the detection of BMI than BMB (92.3% vs. 38.5%). It can be consid-
ered a discriminatory Pre-BMB test with a negative predictive value of 97.6%. In addition,
BMI by PET had a prognostic value with strong correlation with progression-free survival
(PFS) (HR = 3.81; p = 0.013) and overall survival (OS) (HR = 4.12; p = 0.03) while the BMB
had not. PET shows superior performance to the BMB for the detection of marrow involve-
ment in DLBCL. It may be considered as the first line examination of bone marrow instead of
the biopsy.
Introduction
Diffuse large B cell lymphoma (DLBCL) is the most common Non-Hodgkin Lymphoma, rep-
resenting nearly 30% of all Non- Hodgkin Lymphoma in Lebanon [1]. The evaluation of bone
marrow involvement (BMI) is paramount in the case of DLBCL for prognostic and therapeutic
reasons [2]. The current recommendations, such as those of the European Society of Medical
Oncology, insist on bone marrow biopsy (BMB) in the initial evaluation of all patients diag-
nosed with DLBCL [3].
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This intervention remains an invasive and painful procedure with a significant number of
complications [4]. Although the PET/CT scanner (PET) is now a routine procedure for the
staging of DLBCL with prognostic and therapeutic implications as well as for post-treatment
assessment, its role in BMI as a non-invasive examination remains a current debate in oncol-
ogy clinic. The aim of this study is to evaluate the correlation between PET and BMB in detect-
ing BMI in patients with DLBCL. A secondary objective is to assess the prognostic value of
BMI detected by PET on patients’ survival with an ultimate goal of verifying the eligibility of
some hypotheses found in the literature.
Methods
Study design
This study is a retrospective study performed in a single institution in Beirut- LEBANON. All
patients diagnosed with DLBCL between 2009 and 2013, who have undergone a pre-therapeu-
tic PET and BMB were included into the analysis. A total of 54 patients were identified.
Variables
In addition to sociodemographic variables such as age and gender, data were collected on the
clinical characteristics of cases. Variables under this section were: staging, International Prog-
nostic Index (IPI), the presence of B symptoms (fever, weight loss, night sweats) as well as the
the presence of bulky disease, splenic and extra nodal involvement. All these variables were
collected from the hospital medical records. Moreover, bone marrow involvement (BMI) was
considered as the main independent variable that was blindly assessed based on PET and
BMB. Only one PET scan machine was used in the staging of DLBCL lymphoma and the
results were blindly read twice independently from the course of the disease in the same radiol-
ogy department by at least two “nuclear medicine specialists” with more than 15 years of expe-
rience in PET/CT scan: the first reading in the period of disease staging (information were
collected from the PET reports signed by two different physicians) and the second one during
this study to verify the findings. None of the PET scan results was found to be inaccurate dur-
ing the proofreading. Positive lesion on PET scan was defined as a focal increased uptake or
diffuse increased heterogeneous bone marrow uptake greater than liver uptake with a mean
SUV max of more than 3.8. As for the bone marrow biopsy, the results were read only in the
staging period in an accredited pathology laboratory that follows international guidelines and
has decades of experience. The study used the pathology reports and did not verify retrospec-
tively the results since pathology findings are not currently debated and are already valid. All
the included biopsies were adequate since they had a bone marrow core with a size of more
than 0.5 cm.
Statistical analysis
Two analysis were conducted for the sensitivity/specificity of the tests to investigate a potential
difference between the current recommendations of assessing the bone marrow involvement
by the biopsy and an eventual role of PET scan in this assessment. As for the prognostic value
of the two exams, the log-rank test was used in the survival analysis and Hazard Ratios (HR)
were reported to compare between sub-groups. The statistical analyses were tested with PASW
(Version 18) software.
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Ethical considerations
The study was in accordance with the ethical standards of the institutional research committee
and with the Helsinki declaration. For this type of study, formal consent is not required.
Results
Patients characteristics
Demographic and clinical data. Among the 54 patients diagnosed with DLBCL, 29
(54%) were men. Mean age was 50 years (16–87).
The majority of patients had stage IV disease at diagnosis (41%), while stages I, II and III
were diagnosed in 18.5%, 22% and 18.5% respectively. Bulky disease, splenic involvement
and extranodal disease were present in 30%, 7% and 48% of patients respectively. All
patients were treated with R-CHOP based regimen. Patients’ characteristics are detailed in
Table 1.
Survival analysis. After a mean follow up of 30-months, 12 out of 48 patients (25%) devel-
oped a relapse of their disease and 8 died. The 1- and 2- year progression-free survival (PFS)
were 77% and 1- and 2- years overall survival (OS) were 95% and 84% respectively.
Features of BMI. PET detected BMI in 12 patients (22%) with only 1 patient showing dif-
fuse infiltration. BMB detected BMI in 5 patients only (9%); 4 of which having also marrow
involvement on PET. 41 patients had a negative BMB and a negative PET exam. Concordance
rate between PET and BMB is 83.3% (45 of 54 patients). Table 2 shows the characteristics of
marrow involvement detected by PET and/or BMB.
Table 1. Demographic and clinical patient characteristics.
Gender Male, n (%) 25 (46)
Female, n (%) 29 (54)
Age Mean ± SD, years Range, years 50±19 16–87
Stage I, n (%) 10 (18.5)
II, n (%) 12 (22)
III, n (%) 10 (18.5)
IV, n (%) 22 (41)
B Symptoms, n (%) 7 (13)
Bulky disease, n (%) 16 (29)
Splenic disease, n (%) 4 (7)
Extranodal disease, n (%) 26 (48)
International Prognostic Index (IPI) Mean± SD
Range
2±1
0–4
doi:10.1371/journal.pone.0170299.t001
Table 2. Characteristics of bone marrow involvement.
Characteristics of bone marrow involvement on PET and BMB n (%)
PET + / BMB - 8 (15)
PET + / BMB + 4 (7)
PET − / BMB + 1 (2)
PET − / BMB - 41 (76)
Total 54
doi:10.1371/journal.pone.0170299.t002
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Correlation analysis of the detection of BMI by PET and BMB
If we consider BMB as the gold standard and the only true positive procedure for detecting
BMI, PET showed sensitivity and specificity of 80%. The negative predictive value of this test
would be 98% and the positive predictive value would be 33%.
If we consider any BMI as a true positive whether detected by BMB or PET, PET sensitivity
would be of 92% (12/13) vs. 38% (5/13) for the BMB. The specificity would be of 100% for
both exams.
An assessment of the concordance between the PET and BMB results was also performed
using Receiver Operating Characteristic curve. Analysis showed weak but significant concor-
dance between PET and BMB (kappa = 0.391< 0.6 with p = 0.001). The discriminative power
of PET for BMI when considering BMB as gold standard exam was 0.82> 0.5 (p = 0.02).
Prognostic values of BMB and PET and correlation with the 2-year
survival rate
Prognostic value of the BMB and PET on PFS. Mean PFS of patients with positive and
negative BMI by BMB was identical. The Hazard Ratio (HR) for relapse according to BMB was
0.61 (CI 95% [0.13–2.78]; p = 0.517).
There was a significant difference for disease relapse between patients with positive and
negative BMI detected by PET. The mean PFS of patients with or without BMI on PET was
16.2 and 21.2 months respectively. HR was 3.81, CI 95% [1.23–11.87] and p = 0.013 (Fig 1).
Prognostic value of the BMB and PET on OS. Mean OS of patients with positive and
negative BMI by BMB was identical. HR for death according to BMB was 0.83 (CI 95% [0.10–
6.77]; p = 0.864).
There was a significant difference for the risk of death between patients with positive and
negative BMI detected by PET. The mean OS of patients with or without BMI on PET were
19.2 and 23.3 months respectively. HR was 4.12, CI 95% [1.03–16.5] and p = 0.03 (Fig 2).
Discussion
This retrospective study aims to compare the accuracy of lymphoma BMI detection by BMB
and PET. A specialized nuclear radiologist reviewed PET imaging of 54 patients with DLBCL
who have a PET scanner and BMB performed before therapy. Our study showed discordance
between the two examinations with PET showing an excellent sensitivity (92%) and a very
Fig 1. PFS curves. The PFS curves are provided according to the result of bone marrow involvement (a)
BMB results (HR: 0.61 [0.13–2.78]; p = 0.517) (b) PET results (HR: 3.81 [1.23–11.87]; p = 0.013).
doi:10.1371/journal.pone.0170299.g001
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high negative predictive value (98%) when compared to BMB. BMI by PET had a negative
impact on PFS and OS while BMB had no predictive effect.
Our results are concordant with other trials that questioned the value of the BMB as a single
examination for assessing BMI in the NHL and especially DLBCL. Our mismatch rate of 17%
(9 of 54 patients) between PET and BMB in the detection of BMI is similar to the one found in
the study of Hong et al [5] where the rate was 19%. Many explanations for this discrepancy
were postulated, such as the small size of the sample obtained during a “blind” biopsy [6] and
the focal disease of bone marrow involvement, away from the iliac crest that represents 92%
(11 of 12 patients) of cases of marrow involvement detected by PET in our series. There is no
current debate in the literature about the quality of the biopsy. It is not the reason behind re-
considering the use of BMB in patients with DLBCL. Its invasive nature and its limitation to
the assessment of one region in the body are the main problems that pushed scientists to evalu-
ate other alternatives such as PET/CT scan.
Our results are also in line with the meta- analysis reported by Adams et al [8] with a high
PET sensitivity (92%) and high negative predictive value (98%).
The discriminative power of PET for BMI when considering BMB as gold standard exam
using Receiver Operating Characteristic was 0.82 > 0.5 (p = 0.02) which indicates that PET
can be considered a good discriminatory pre-BMB. These results allow us to suggest that PET
could be a first-line evaluation tool for BMI in DLBCL patients: a negative result cancels the
indication of the BMB while a positive result shows an indication for a targeted biopsy or MRI
in focal involvement and a blind bone marrow biopsy in diffuse disease (Fig 3).
By excluding the systematic BMB from the baseline work-up of newly diagnosed DLBCL
and considering the PET as the only method to assess the bone marrow, an estimation of 3%
of cases having bone marrow involvement would be unrevealed. [7]. However, this would not
result in any modification in patients’ therapeutic plan [8,9].
Although this study had a relatively small sample size, it generated data on a potential prog-
nostic value of BMI revealed by PET. It showed that a PET exam showing a positive BMI was
associated to more frequent events of disease relapse and death at 2 years with HR 3.81 and
4.12 respectively. This result was also found by Berthet et al [10]. The study compared the PFS
and OS at 2 years in 133 patients according to bone marrow invasion by BMB and PET. Their
Fig 2. OS curves. OS curves are provided according to the result of bone marrow involvement. (a) BMB results (HR: 0.83
[0.10–6.77]; p = 0.864) (b) PET results (HR: 4.12 [1.03–16.5]; p = 0.03).
doi:10.1371/journal.pone.0170299.g002
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study showed that bone marrow disease on PET was an independent prognostic factor for PFS
and OS. However, this result was also true for BMB, which contradicts our results.
Three other studies have evaluated the effect of BMI by PET and BMB on the disease prog-
nosis. Adams et al [11] in a series of 78 patients reported that BMI on PET had no prognostic
value. Only BMI by BMB was an independent predictive factor and it has even exceeded the
effect of IPI score according to their study. The lack of significant difference in PFS and OS
according to BMI on PET was also noticed by the series of Hong et al. In addition, Khan et al
[8] assessed the survival of 44 patients with stage IV and found that patients with BMI on PET
had similar PFS and OS to patients with stage IV without BMI; however, the positivity of BMB
had a pejorative additional effect in the population studied.
Our study population was homogenous and a retrospective review of PET was performed
for BMI re-assessment. Retrospective analysis with a mean of 30 months was sufficient to cor-
relate results of BMB and PET with the survival of patients, a new concept not well studied so
far in the literature. Our study aimed to establish a new hypothetical recommendation for
patients with DLBCL to find an alternative to an invasive and painful technique.
The study has several limitations. The retrospective nature of the study prevented us to
expand the patients monitoring. The study also failed to realize targeted bone marrow biopsy
for focal involvement detected on PET for histological confirmation, which was also seen in
other studies. Finally, the number of patients included in all studies including ours, is a major
limitation regarding the generalization of the results; therefore, more robust prospective stud-
ies are needed to assess if a BMI detected by PET according to multiple nuclear specialists
could have an independent prognostic value on patients’ survival. Future research should also
evaluate the effects of each type of BMI on PET (focal and diffuse) independently after adjust-
ing for other predictors of patients’ survival.
The study, although retrospective, concluded that PET read by specialists has an excellent
sensitivity for detecting BMI in DLBCL. This sensitivity is superior to BMB especially in the
case of focal disease and sparing of the iliac crests. The BMI detected by PET has also showed
in our series a prognostic value correlated with patient survival. Blind BMB might be unneces-
sary in the era of nuclear imaging; hence, the need to review its systematic indication in staging
of DLBCL. We suggest a theoretical algorithm for the evaluation of BMI in DLBCL: a negative
PET result for BMI should eliminate the need for BMB; only patients with BMI on PET will
Fig 3. BMI evaluation. Proposed algorithm for the evaluation of Bone Marrow Involvement (BMI) in DLBCL patients.
doi:10.1371/journal.pone.0170299.g003
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benefit from a targeted biopsy in focal involvement or a blind biopsy in case of diffuse involve-
ment. This algorithm should be evaluated in a prospective study or revalidated in a large retro-
spective study to be possibly adopted in the recommendations for staging.
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